Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...

SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, ...

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the ...

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

The injectable drug market is projected to grow from USD 630.9 billion in 2025 to USD 1,048.5 billion by 2035, reflecting a CAGR of 5.8%. This growth is driven by rising demand for biologics, vaccines ...

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be ...

The FDA on Wednesday approved a highly effective long-acting shot for HIV prevention that is administered just twice per year ...

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...